+44 7868 792050
Mohammed Abdul Waheed
Central Research Institute of Unani Medicine, India
Posters & Accepted Abstracts: J Clin Exp Dermatol Res
Vitiligo, histologically is characterized by loss of melanocytes with diminished or absent activity of melanocyte tyrosinase on the melanin pigment precursor dihydroxy phenyl alanine (DOPA). Worldwide, prevalence of vitiligo is of 0.5-1.0%; 1 in 136 or 0.74% or 2 million people in USA. In India, incidence of vitiligo is around 0.5-2.5%. The ratio of males and females is 1:1 and the age at onset is 20 or 30 years and 50% of the disease population develops their full clinical picture before attaining their early adult life. A disorder consisting of areas of macular depigmentation, commonly on extensor aspects of extremities, on the face or neck and in skin folds involving unilateral, bilateral, symmetrical distribution. Emotional distress and discrimination is also usually associated with vitiligo. Therefore, it is important to develop immune modulators to control the aggravation of the disease, melanogenic drugs to induce repigmentation at the same time to overcome the resistance phase.